Press Releases

May 03, 2023

Veracyte Announces Release of Inaugural ESG Report

Read More

May 02, 2023

Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer

Read More

May 01, 2023

Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference

Read More

Apr 29, 2023

Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

Read More

Apr 27, 2023

Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting

Read More

Apr 17, 2023

New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

Read More

Apr 13, 2023

Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023

Read More

Apr 12, 2023

Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

Read More

Apr 10, 2023

C2i Genomics Study Finds Circulating Tumor DNA Can Predict Treatment Outcomes in Patients with Locally Advanced Rectal Cancer Enrolled for Organ Preservation

Read More

Mar 15, 2023

Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners

Read More